However, clinical studies have revealed that although anti-inflammatory treatment of type 2 diabetic patients with recombinant IL-1Ra (Anakinra) produced modest reductions in glycated hemoglobin, no difference in insulin sensitivity was observed compared with placebo [12], [13]. The gene discussed is INS; the disease is type 2 diabetes mellitus.